Can-Fite notes longer blinded survival in Phase III liver cancer trial
Can-Fite BioPharma Ltd. (CANF) reported that blinded overall survival in its ongoing pivotal Phase III study of Namodenoson in advanced hepatocellular carcinoma appears longer than originally anticipated versus the assumptions used in the study design.
Rhea-AI Filing Summary
Can-Fite BioPharma Ltd. (CANF) reported that blinded overall survival in its ongoing pivotal Phase III study of Namodenoson in advanced hepatocellular carcinoma appears longer than originally anticipated versus the assumptions used in the study design. The randomized, double-blind, placebo-controlled trial enrolls patients with advanced HCC and underlying Child-Pugh B7 cirrhosis, with overall survival as the primary endpoint.
The current observation is based on pooled, blinded data from both Namodenoson and placebo arms, so no efficacy conclusions or between-arm differences can be drawn at this stage. In response to the longer-than-anticipated survival, Can-Fite plans to evaluate an earlier timing for the study’s planned interim analysis, which will allow an independent assessment of overall survival between treatment groups under the predefined statistical analysis plan and regulatory requirements.
Positive
- None.
Negative
- None.
Key Figures
Trial phase: Phase III
Randomization ratio: 2:1 Namodenoson to placebo
Cirrhosis classification: Child-Pugh B7
+2 more
5 metrics
Trial phase
Phase III
Pivotal study of Namodenoson in advanced hepatocellular carcinoma
Randomization ratio
2:1 Namodenoson to placebo
Design of the pivotal Phase III hepatocellular carcinoma trial
Cirrhosis classification
Child-Pugh B7
Underlying liver function status of enrolled hepatocellular carcinoma patients
Development stage Piclidenoson
Phase 3 trial commenced
Lead candidate Piclidenoson in psoriasis
Clinical exposure across programs
More than 1,600 patients
Patients treated with the company’s drugs in clinical studies to date
Key Terms
overall survival, pivotal Phase III study, hepatocellular carcinoma, Orphan Drug Designation, +2 more
6 terms
overall survival medical
"blinded overall survival observed across the entire patient population"
Overall survival is the average or median length of time patients remain alive after starting a treatment or entering a clinical study, measured regardless of cause of death. Investors care because it is a clear, hard measure of a therapy’s real-world benefit — like timing how long a new battery actually runs — and strong improvements in overall survival can drive regulatory approval, market adoption and revenue potential.
pivotal Phase III study medical
"blinded overall survival observed across the entire patient population in its ongoing pivotal Phase III study"
hepatocellular carcinoma medical
"pivotal Phase III study of Namodenoson in advanced hepatocellular carcinoma (HCC)"
Hepatocellular carcinoma is the most common form of primary liver cancer, arising from the main functional cells of the liver. For investors it matters because its serious health impact drives demand for diagnostic tests, treatments and long-term care; progress in trials or approvals can change a drugmaker’s revenue outlook much like a successful product launch can reshape a company’s future.
Orphan Drug Designation regulatory
"Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
Fast Track Designation regulatory
"Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
Metabolic Dysfunction-associated Steatohepatitis (MASH) medical
"Phase 2b trial for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH)"
Metabolic dysfunction-associated steatohepatitis (MASH) is a liver condition characterized by inflammation and fat buildup caused by metabolic issues like obesity and insulin resistance. It can lead to liver damage over time, similar to rust gradually weakening metal. Because it is linked to widespread health problems such as diabetes and heart disease, MASH is becoming an important factor in overall health risks and healthcare costs, which can impact economic and investment considerations.
FAQ
What did Can-Fite BioPharma (CANF) announce about its Phase III liver cancer trial?
Can-Fite reported that blinded overall survival in its pivotal Phase III Namodenoson trial in advanced hepatocellular carcinoma appears longer than originally anticipated compared with the assumptions used in the study design, based on pooled data from both Namodenoson and placebo arms.
Does the new survival information in CANF’s study show Namodenoson is effective?
No. The company states the observation is based on pooled, blinded data including both Namodenoson and placebo, so no conclusions about Namodenoson’s treatment effect or differences between study arms can be drawn at this stage.
What change is Can-Fite (CANF) considering for the Namodenoson Phase III trial?
In view of the longer-than-anticipated survival in the study population, Can-Fite is evaluating an earlier timing for the trial’s planned interim analysis, which would allow an independent assessment of overall survival between Namodenoson and placebo groups.
What is the design of Can-Fite’s pivotal Phase III Namodenoson liver cancer trial?
The trial is a randomized, double-blind, placebo-controlled Phase III study in advanced hepatocellular carcinoma with underlying Child-Pugh B7 cirrhosis. Patients are randomized 2:1 to receive Namodenoson or placebo, and overall survival is the primary efficacy endpoint.
What other indications is Namodenoson being studied for by CANF?
Namodenoson is being evaluated in a pivotal Phase III trial for advanced liver cancer, has concluded a Phase 2a study in pancreatic cancer, and is enrolling in a Phase 2b trial for Metabolic Dysfunction-associated Steatohepatitis (MASH).
What regulatory designations has Namodenoson received according to CANF?
Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation by the U.S. FDA as a second-line treatment for hepatocellular carcinoma, as disclosed by Can-Fite.
AI-generated analysis. How Rhea-AI works. Not financial advice.
